Vir Biotechnology, Inc. Stockholders Equity

Quick Answer

Vir Biotechnology, Inc. reported Stockholders Equity of $765.28 million for fiscal year 2025.

Vir Biotechnology, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $765.28M -33.5%
2024 $1.15B -27.7%
2023 $1.59B -23.5%
2022 $2.08B +45.1%
2021 $1.43B +99.7%
2020 $716.85M +69.1%
2019 $423.94M +336.6%
2018 -$179.18M -160.0%
2017 -$68.92M -764.5%
2016 -$7.97M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $796.10M -35.8% -16.0%
June 30, 2025 $947.47M -33.9% -9.2%
March 31, 2025 $1.04B -32.5% -9.3%
December 31, 2024 $1.15B -27.7% -7.3%
September 30, 2024 $1.24B -25.9% -13.5%
June 30, 2024 $1.43B -20.8% -7.3%
March 31, 2024 $1.55B -21.5% -2.7%
December 31, 2023 $1.59B -23.5% -5.1%
  • Vir Biotechnology, Inc. showed a decrease of -33.5% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2016–2025 period, Vir Biotechnology, Inc.’s stockholders equity has grown by 9699.5% (from -$7.97 million to $765.28 million).
  • The most recent figure is from Vir Biotechnology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 23, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment